Intellia Therapeutics
NTLA
364 hedge funds and large institutions have $8.34B invested in Intellia Therapeutics in 2021 Q3 according to their latest regulatory filings, with 73 funds opening new positions, 130 increasing their positions, 113 reducing their positions, and 42 closing their positions.
74% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 42
15% more repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 113
9% more funds holding
Funds holding: 335 → 364 (+29)
6% more call options, than puts
Call options by funds: $99.9M | Put options by funds: $94M
6.79% less ownership
Funds ownership: 91.42% → 84.63% (-6.8%)
17% less capital invested
Capital invested by funds: $10B → $8.34B (-$1.68B)
33% less funds holding in top 10
Funds holding in top 10: 12 → 8 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$89.2M |
| 2 |
BlackRock
New York
|
+$85.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$68.4M |
| 4 |
Morgan Stanley
New York
|
+$67.9M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$56.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$168M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$142M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$110M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
-$100M |
| 5 |
JP Morgan Chase
New York
|
-$61M |
NTLA Hedge Fund Activity: Q3 2021 in Review
364 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q3 2021, worth a combined $8.34B — down 17% from $10B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new NTLA positions and 42 closed out — a net gain of 31 holders — while 130 added to existing stakes and 113 trimmed.
The largest buyer was Franklin Resources, adding an estimated $89.2M. The largest seller was Darwin Global Management, cutting an estimated $168M.
- 364 institutional investors held Intellia Therapeutics (NTLA) as of Q3 2021, up from 335 in Q2 2021.
- Funds reported $8.34B of Intellia Therapeutics stock for Q3 2021, down 17% quarter-over-quarter.
- 73 funds opened new Intellia Therapeutics positions in Q3 2021 and 42 closed out, a net change of +31 holders.
- The largest Intellia Therapeutics buyer in Q3 2021 was Franklin Resources, an estimated $89.2M added.
- The largest Intellia Therapeutics seller in Q3 2021 was Darwin Global Management, an estimated $168M sold.
Based on aggregated 13F filings for Q3 2021.